Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.

Khaled M. Ramadan, Joseph M. Connors, Abdulwahab J. Al-Tourah, Randy D. Gascoyne, Kevin Song, Michael J. Barnett, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Julye Lavoie, Donna L. Forrest, Donna E. Hogge, Nicholas J. Voss, Clayton A. Smith, Cynthia L. Toze

Blood (2006) 108 (11): 3039.

https://doi.org/10.1182/blood.V108.11.3039.3039

Published: 2006

Journal Articles

Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Khaled M. Ramadan, Joseph M. Connors, Randy D. Gascoyne, Kevin Song, Michael J. Barnett, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Julye Lavoie, Donna L. Forrest, Donna E. Hogge, Nicholas J. Voss, Ryan Brinkman, Clayton A. Smith, Cynthia L. Toze

Blood (2006) 108 (11): 3139.

https://doi.org/10.1182/blood.V108.11.3139.3139

Published: 2006

Journal Articles

Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Blood (2006) 108 (11): 3662.

https://doi.org/10.1182/blood.V108.11.3662.3662

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.

Kevin W. Song, MD, Thomas J. Nevill, MD, Randy D. Gascoyne, MD, Cynthia L. Toze, MD, Michael B. Barnett, MD, Donna L. Forrest, MD, Donna E. Hogge, MD, Julye C. Lavoie, MD, Stephen H. Nantel, MD, John D. Shepherd, MD, Clayton A. Smith, MD, Heather J. Sutherland, MD, Nicholas J. Voss, MD, Joseph M. Connors, MD

Blood (2004) 104 (11): 900.

https://doi.org/10.1182/blood.V104.11.900.900

Published: 2004

Journal Articles

Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy.

Cynthia L. Toze, Donna E. Hogge, Michael J. Barnett, Thomas J. Nevill, Stephen H. Nantel, Heather J. Sutherland, John D. Shepherd, Kevin W. Song, Donna L. Forrest, Julye C. Lavoie, Joseph M. Connors, Randy D. Gascoyne, Nicholas J. Voss, Clayton A. Smith

Blood (2004) 104 (11): 2764.

https://doi.org/10.1182/blood.V104.11.2764.2764

Published: 2004

NARROW

Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.

Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.

Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy.

Email alerts

ASH Publications

American Society of Hematology

Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.

Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.

Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only